TGA CTN Scheme vs. Latin America: Real First-Patient-In Timelines

The notification is fast. The program is not the notification. First-patient-in equals clearance plus activation plus enrollment.

September 5, 2026

7

min read

By

Julio G. Martinez-Clark, CEO, bioaccess®

Australia

Latin America

First-in-Human

Regulatory

Panama

Medical Devices

Is the TGA CTN scheme actually fast?

Yes. Say it plainly: Australia's Clinical Trial Notification scheme is genuinely fast, and the regulatory step is not the problem in an Australian program. The TGA runs a notification pathway rather than a full pre-approval review for eligible trials, and sponsors who complain about Australian timelines are almost never complaining about the TGA. The agency is competent, the pathway is well documented, and Australian investigators, sites, and ethics committees produce high-quality data.

This article does not argue otherwise, and it is not a criticism of the TGA. It is a measurement argument. If you benchmark countries on notification speed, Australia looks like the obvious answer. If you benchmark them on the date your first patient is treated, the ranking changes — and the second number is the one your board actually cares about.

The frame: a fast notification is a fast start to the paperwork. It is not a fast start to the study.

What does first-patient-in actually measure?

First-patient-in (FPI) is the date the first participant is treated under the protocol. It is the moment data begins accruing, which means it is the moment your program starts converting cash into evidence. FPI decomposes into three terms:

• Regulatory clearance — the notification or approval that permits the study to proceed.
• Site activation — ethics coordination, contracting, import permits for the device and supplies, investigator and staff training, monitoring setup, source-document and system readiness.
• Patient enrollment — screening throughput against your inclusion and exclusion criteria until the first eligible participant consents and is treated.

A fast notification shortens exactly one of those three terms. It does not shorten contracting. It does not shorten import clearance. It does not shorten investigator training or screening. And those downstream stages are where first-in-human programs actually stall — not at the regulator's desk.

How do the stages compare side by side?

How fast does activation run in Latin America?

Here are the activation numbers we actually work from. In Panama, bioaccess® has seen trial activations in 15-30 days post-submission. One UK/Oxford neurology sponsor activated in about 15 days. Panama MINSA approvals typically run about 30-60 days. In El Salvador, the SRS pathway runs 30-90 days post-submission.

Note what those figures describe. They are not regulator response times in isolation — they are the interval from submission to a site that is ready to treat. That is the number that maps onto FPI, because the same in-country team is running the submission, the contracting, the import permits, the training, and the monitoring setup in parallel rather than in sequence.

That is the structural difference. When regulatory work, site readiness, and logistics sit with one accountable in-country partner, activation compresses. When they sit with a sponsor coordinating separate entities from 14-16 time zones away, activation expands — regardless of how quickly the notification cleared.

Why does enrollment decide the schedule?

Even a perfectly activated site enrolls at the rate its catchment allows. Enrollment speed is a function of how many eligible people live within a workable travel radius of the clinic, how many competing protocols are drawing on that same pool, and how many candidates the unit can screen per week. None of those variables respond to regulatory speed.

This is where the arithmetic favors dense Latin American metros, and we work the numbers in detail in the Australian catchment math. Sponsors who optimized for the fast notification and then discovered the enrollment curve are the subject of the three years lost in Australia before moving first-in-human to Latin America.

What is the honest takeaway?

Compare programs on first-patient-in and cost-to-enroll, not on notification speed alone. Ask every candidate country for a projected FPI date and a projected cost per enrolled participant, and make them defend both. Notification turnaround is a component of the first number and irrelevant to the second.

A useful decision rule: choose Australia when you already have Australian infrastructure and the local candidate pool clearly fits your criteria — the TGA pathway and Australian data quality are real advantages in that case. Choose Latin America when FPI certainty, low sponsor effort, and US-adjacent oversight matter more. On that basis, a dense Latin American catchment paired with 15-30 day activation beats a fast Australian notification followed by slow recruitment.

For the full head-to-head across cost, catchment, diversity, travel, and entity requirements, start with the pillar: Australia vs. Latin America for first-in-human medical device trials. For the wider option set, see alternatives to Australia for first-in-human trials in 2026.

Frequently asked questions

What is the fastest next step?

Send us your protocol synopsis, your cohort size, and your target FPI date, and we will tell you which pathway gets you there — including the cases where staying in Australia is the right call. Get a first-in-human feasibility read in 72 hours.

Get your feasibility read

See our Panama sites